Patents Assigned to Acorda Therapeutics
  • COMPOSITIONS AND METHODS OF USING CHONDROITINASE ABCI MUTANTS
    Publication number: 20170028038
    Abstract: The present disclosure relates to protein and nucleic acid mutants of chondroitinase ABCI. Such nucleic acid mutants encode for chondroitinase ABCI mutant enzymes exhibiting altered chondroitin lyase activity or increased resistance to inactivation from stressors including UV light or heat. Methods of using such nucleic acid mutants encoding chondroitinase ABCI mutant enzymes is also provided.
    Type: Application
    Filed: August 5, 2016
    Publication date: February 2, 2017
    Applicant: ACORDA THERAPEUTICS, INC.
    Inventors: Anthony O. CAGGIANO, Andrea VECCHIONE, Jennifer IACI
  • Compositions and kits for the removal of irritating compounds from bodily surfaces
    Patent number: 9549893
    Abstract: The invention provides compositions, methods and kits for the removal of harmful or irritating substances from bodily surfaces. Kits may include a composition containing capsaicin and a capsaicin-cleansing composition, e.g., a composition in which capsaicin is soluble.
    Type: Grant
    Filed: November 14, 2014
    Date of Patent: January 24, 2017
    Assignee: Acorda Therapeutics, Inc.
    Inventors: Arturo J. Angel, Larry W. Litle, Keith R. Bley, Allan L. Wilcox, Gene C. Jamieson, Naweed Muhammad
  • COMPOSITIONS AND METHODS OF USING CHONDROITINASE ABCI MUTANTS
    Publication number: 20170009222
    Abstract: One aspect of the present invention relates to mutants of chondroitinase ABCI. Such chondroitinase ABCI mutants exhibit altered chondroitin lyase activity or increased resistance to inactivation from stressors including exposure to UV light or heat. Methods of using chondroitinase ABCI mutant enzymes are also provided.
    Type: Application
    Filed: July 21, 2016
    Publication date: January 12, 2017
    Applicant: Acorda Therapeutics, Inc.
    Inventors: Anthony O. CAGGIANO, Jennifer IACI, Andrea VECCHIONE, Elizabeth HUNTER
  • Proteoglycan degrading mutants for treatment of CNS
    Patent number: 9528102
    Abstract: The present disclosure relates to the preparation and deletion mutants of chondroitinase proteins and their use in methods for promoting the diffusion of therapeutic composition into tissues and their use for neurological functional recovery after central nervous system (“CNS”) injury or disease.
    Type: Grant
    Filed: February 24, 2014
    Date of Patent: December 27, 2016
    Assignee: Acorda Therapeutics, Inc.
    Inventors: Elliott A. Gruskin, Rohini D'Souza, Gargi Roy, Anthony O. Caggiano
  • Compositions and methods for treatment during non-acute periods following CNS neurological injury
    Patent number: 9498515
    Abstract: This invention relates to treatment of neuroinjury in a post-acute window or in a chronic period following neuroinjury.
    Type: Grant
    Filed: August 17, 2009
    Date of Patent: November 22, 2016
    Assignee: Acorda Therapeutics, Inc.
    Inventors: Anthony Caggiano, Jennifer Iaci
  • METHODS FOR TREATING AN IMPAIRMENT IN GAIT AND/OR BALANCE IN PATIENTS WITH MULTIPLE SCLEROSIS USING AN AMINOPYRIDINE
    Publication number: 20160303097
    Abstract: Disclosed herein is use of one or more aminopyridines in methods and compositions for treatment of impairments in gait or balance in patients with multiple sclerosis.
    Type: Application
    Filed: June 29, 2016
    Publication date: October 20, 2016
    Applicant: Acorda Therapeutics, Inc.
    Inventors: Gabriel Pardo, Gustavo Adolfo Suarez Zambrano, Cecilie Fjeldstad
  • Compositions and methods for promoting neuronal outgrowth
    Patent number: 9468671
    Abstract: Neural outgrowth in the central nervous system is achieved by administering chondroitinase AC and/or chondroitinase B to degrade chondroitin sulfate proteoglycans that inhibit or contribute to the inhibition of nervous tissue regeneration.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: October 18, 2016
    Assignee: Acorda Therapeutics, Inc.
    Inventors: Elliott A. Gruskin, Jennifer F. Iaci, Andrea M. Vecchione, Sarah J. Kasperbauer, Gargi Roy
  • COMPOSITIONS AND METHODS FOR PROMOTING NEURONAL OUTGROWTH
    Publication number: 20160279210
    Abstract: Neural outgrowth in the central nervous system is achieved by administering chondroitinase AC and/or chondroitinase B to degrade chondroitin sulfate proteoglycans that inhibit or contribute to the inhibition of nervous tissue regeneration.
    Type: Application
    Filed: June 10, 2016
    Publication date: September 29, 2016
    Applicant: Acorda Therapeutics, Inc.
    Inventors: Elliott A. GRUSKIN, Jennifer F. IACI, Andrea M. VECCHIONE, Sara J. KASPERBAUER, Gargi ROY
  • Compositions and methods of using chondroitinase ABCI mutants
    Patent number: 9410141
    Abstract: The present disclosure relates to protein and nucleic acid mutants of chondroitinase ABCI. Such nucleic acid mutants encode for chondroitinase ABCI mutant enzymes exhibiting altered chondroitin lyase activity or increased resistance to inactivation from stressors including UV light or heat. Methods of using such nucleic acid mutants encoding chondroitinase ABCI mutant enzymes is also provided.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: August 9, 2016
    Assignee: Acorda Therapeutics, Inc.
    Inventors: Anthony O. Caggiano, Andrea Vecchione, Jennifer Iaci
  • Compositions and methods of using chondroitinase ABCI mutants
    Patent number: 9402886
    Abstract: One aspect of the present invention relates to mutants of chondroitinase ABCI. Such chondroitinase ABCI mutants exhibit altered chondroitin lyase activity or increased resistance to inactivation from stressors including exposure to UV light or heat. Methods of using chondroitinase ABCI mutant enzymes are also provided.
    Type: Grant
    Filed: September 8, 2014
    Date of Patent: August 2, 2016
    Assignee: Acorda Therapeutics, Inc.
    Inventors: Anthony O. Caggiano, Jennifer Iaci, Andrea Vecchione, Elizabeth Hunter
  • Methods for detecting cardiac damage
    Patent number: 9329171
    Abstract: The present invention relates to a method for detecting heart damage in a patient. The invention also relates to methods for treatment of patients identified as having heart damage. The invention further pertains to methods for evaluating the efficacy of an ongoing therapeutic regimen designated to treat a damaged heart in a patient.
    Type: Grant
    Filed: January 13, 2014
    Date of Patent: May 3, 2016
    Assignee: Acorda Therapeutics, Inc.
    Inventors: Xinhua Yan, Anthony O. Caggiano
  • Carbonate prodrugs and methods of using the same
    Patent number: 9289501
    Abstract: The present invention provides carbonate prodrugs which comprise a carbonic phosphoric anhydride prodrug moiety attached to the hydroxyl or carboxyl group of a parent drug moiety. The prodrugs may provide improved physicochemical properties over the parent drug. Also provided are methods of treating a disease or condition that is responsive to the parent drug using the carbonate prodrugs, as well as kits and unit dosages.
    Type: Grant
    Filed: February 23, 2015
    Date of Patent: March 22, 2016
    Assignee: Acorda Therapeutics, Inc.
    Inventors: Naweed Muhammad, Keith R. Bley
  • METHODS FOR TREATING AN IMPAIRMENT IN GAIT AND/OR BALANCE IN PATIENTS WITH MULTIPLE SCLEROSIS USING AN AMINOPYRIDINE
    Publication number: 20160067230
    Abstract: Disclosed herein is use of one or more aminopyridines in methods and compositions for treatment of impairments in gait or balance in patients with multiple sclerosis.
    Type: Application
    Filed: November 12, 2015
    Publication date: March 10, 2016
    Applicant: ACORDA THERAPEUTICS, INC.
    Inventors: Gabriel Pardo, Gustavo Adolfo Suarez Zambrano, Cecilie Fjeldstad
  • METHODS FOR TREATING SENSORIMOTOR IMPAIRMENTS ASSOCIATED WITH CERTAIN TYPES OF STROKE USING AMINOPYRIDINES
    Publication number: 20160058743
    Abstract: Disclosed herein are methods and compositions related to therapeutic use of aminopyridines in patients with stroke-related impairments, in particular, in patients with sensorimotor impairments resulting from certain types of stroke.
    Type: Application
    Filed: April 14, 2014
    Publication date: March 3, 2016
    Applicant: ACORDA THERAPEUTICS, INC.
    Inventors: Andrew R. Blight, Anthony O. Caggiano, Tom J. Parry, Jennifer F. Iaci
  • Method for achieving desired glial growth factor 2 plasma levels
    Patent number: 9272015
    Abstract: The present invention relates to administering glial growth factor 2 (GGF2) to a patient in need thereof, to achieve serum levels of GGF2 within a desired therapeutic window determined based on the disease or disorder afflicting the patient. In a particular embodiment, the patient is suffering from a disease or disorder associated with reduced levels of myelination and the GGF2 is administered to promote myelination in the patient.
    Type: Grant
    Filed: March 29, 2013
    Date of Patent: March 1, 2016
    Assignee: Acorda Therapeutics, Inc.
    Inventors: Haesun Kim, Anthony O. Caggiano
  • Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure
    Patent number: 9198951
    Abstract: The invention relates to treatment of heart failure in a mammal. Accordingly, the invention is directed to establishing a dosing regimen whereby the therapeutic benefits conferred by administration of a neuregulin such as glial growth factor 2 (GGF2) or a subsequence thereof are maintained and/or enhanced, while concomitantly minimizing any potential side effects.
    Type: Grant
    Filed: May 29, 2013
    Date of Patent: December 1, 2015
    Assignee: Acorda Therapeutics, Inc.
    Inventors: Anthony O. Caggiano, Anindita Ganguly, Jennifer Iaci, Tom Parry
  • Compositions and methods of using chondroitinase ABCI mutants
    Patent number: 9102930
    Abstract: The present disclosure relates to protein and nucleic acid mutants of chondroitinase ABCI. Such nucleic acid mutants encode for chondroitinase ABCI mutant enzymes exhibiting altered chondroitin lyase activity or increased resistance to inactivation from stressors including UV light or heat. Methods of using such nucleic acid mutants encoding chondroitinase ABCI mutant enzymes is also provided.
    Type: Grant
    Filed: March 22, 2013
    Date of Patent: August 11, 2015
    Assignee: Acorda Therapeutics, Inc.
    Inventors: Anthony O. Caggiano, Andrea Vecchione, Jennifer Iaci
  • Use of a neuregulin to treat peripheral nerve injury
    Patent number: 9078861
    Abstract: Embodiments of the invention are directed to use of neuregulins to prevent or treat peripheral nerve injury, to attenuate, ameliorate or avoid the loss of peripheral nerve function.
    Type: Grant
    Filed: October 14, 2010
    Date of Patent: July 14, 2015
    Assignee: Acorda Therapeutics Inc.
    Inventors: Anthony O. Caggiano, Anthony J. Bella, Jennifer F. Iaci
  • Acetaminophen conjugates, compositions and methods of use thereof
    Patent number: 9024055
    Abstract: Acetaminophen conjugates are provided, which have an acetaminophen moiety covalently linked to a second moiety. The conjugates provided may have one or more advantageous properties, including increased water solubility as compared to acetaminophen, reduced toxicity profile as compared to acetaminophen and an altered pharmacokinetic profile. Formulations comprising the conjugates are also provided, as are methods of using the conjugates and kits comprising the conjugates.
    Type: Grant
    Filed: September 21, 2012
    Date of Patent: May 5, 2015
    Assignee: Acorda Therapeutics, Inc.
    Inventors: Keith R. Bley, Bernd Jandeleit
  • Carbonate prodrugs and methods of using the same
    Patent number: 8993545
    Abstract: The present invention provides carbonate prodrugs which comprise a carbonic phosphoric anhydride prodrug moiety attached to the hydroxyl or carboxyl group of a parent drug moiety. The prodrugs may provide improved physicochemical properties over the parent drug. Also provided are methods of treating a disease or condition that is responsive to the parent drug using the carbonate prodrugs, as well as kits and unit dosages.
    Type: Grant
    Filed: April 14, 2014
    Date of Patent: March 31, 2015
    Assignee: Acorda Therapeutics, Inc.
    Inventors: Naweed Muhammad, Keith R. Bley